Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

Acute hepatitis Alteraciones neurológicas Chronic hepatitis Embarazo Hepatitis E Hepatitis aguda Hepatitis crónica Interferón pegilado Neurological disorders Pegylated interferon Pregnancy Prevención Prevention Ribavirin Ribavirina Transplantation Trasplante Zoonoses Zoonosis

Journal

Enfermedades infecciosas y microbiologia clinica (English ed.)
ISSN: 2529-993X
Titre abrégé: Enferm Infecc Microbiol Clin (Engl Ed)
Pays: Spain
ID NLM: 101777541

Informations de publication

Date de publication:
Jan 2020
Historique:
received: 05 06 2018
accepted: 06 06 2018
pubmed: 4 8 2018
medline: 30 7 2021
entrez: 4 8 2018
Statut: ppublish

Résumé

Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis in both developed and developing countries. This infectious disease has a high prevalence and incidence in Europe. HEV infection has a greater clinical impact in vulnerable populations, such as immunosuppressed patients, pregnant women and patients with underlying liver disease. Therefore, the Study Group for Viral Hepatitis (Grupo de Estudio de Hepatitis Víricas, GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica, SEIMC) believed it very important to prepare a consensus document to help in decision-making regarding diagnosis, clinical and therapeutic management, and prevention of HEV infection.

Identifiants

pubmed: 30072282
pii: S0213-005X(18)30227-1
doi: 10.1016/j.eimc.2018.06.014
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

28-32

Informations de copyright

Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Auteurs

Antonio Rivero-Juárez (A)

Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain. Electronic address: arjvet@gmail.com.

Antonio Aguilera (A)

Complexo Hospitalario Universitario Santiago (CHUS) & Universidad de Santiago, Santiago de Compostela, Spain.

Ana Avellón (A)

Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.

Miguel García-Deltoro (M)

Consorcio General Hospital Universitario de Valencia, Valencia, Spain.

Federico García (F)

Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria IBS, Granada, Spain.

Christian Gortazar (C)

Instituto de Investigación en Recursos Cinegéticos (IREC-CSIC-UCLM), Ciudad Real, Spain.

Rafael Granados (R)

Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.

Juan Macías (J)

Hospital Universitario Virgen de Valme, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.

Nicolás Merchante (N)

Hospital Universitario Virgen de Valme, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.

José Antonio Oteo (JA)

Hospital Universitario San Pedro, Logroño Centro de investigación Biomédica de La Rioja (CIBIR), Spain.

María Teresa Pérez-Gracia (MT)

Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Valencia, Spain.

Juan Antonio Pineda (JA)

Hospital Universitario Virgen de Valme, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.

Antonio Rivero (A)

Hospital Universitario Reina Sofía de Córdoba, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Cordoba, Spain.

David Rodriguez-Lazaro (D)

Facultad de Ciencias, Universidad de Burgos, Burgos, Spain.

Francisco Téllez (F)

Hospital Universitario Puerto Real, Cádiz, Spain.

Luis E Morano-Amado (LE)

Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, Vigo, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH